Johnson & Johnson has filed a lawsuit against the U.S. Health Resources and Services Administration over a dispute regarding payment methods for hospitals in the federal drug discount program. The company argues that the agency has misinterpreted the federal law concerning rebates in the 340B Drug Pricing Program. Johnson & Johnson recently attempted to change payment terms for its Xarelto and Stelara medications, but the agency claims this would violate the program’s regulations. The HRSA insists that approval from the Department of Health and Human Services is necessary before J&J can implement these changes.
Source link
Johnson & Johnson sues HHS over 340 B payment terms
